Vericel (NASDAQ:VCEL) Earns “Buy” Rating from HC Wainwright

Vericel (NASDAQ:VCEL)‘s stock had its “buy” rating restated by HC Wainwright in a note issued to investors on Friday,Benzinga reports. They currently have a $60.00 target price on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 16.98% from the company’s previous close. HC Wainwright also issued estimates for Vericel’s FY2025 earnings at $0.26 EPS, FY2027 earnings at $1.18 EPS, FY2028 earnings at $1.93 EPS and FY2029 earnings at $2.66 EPS.

VCEL has been the topic of a number of other reports. Stephens restated an “overweight” rating and set a $65.00 price objective on shares of Vericel in a research note on Wednesday, January 15th. Canaccord Genuity Group lifted their target price on Vericel from $64.00 to $67.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. StockNews.com raised Vericel from a “sell” rating to a “hold” rating in a report on Tuesday, December 24th. BTIG Research lifted their target price on Vericel from $56.00 to $66.00 and gave the stock a “buy” rating in a report on Tuesday, November 26th. Finally, Truist Financial lifted their target price on Vericel from $61.00 to $67.00 and gave the stock a “buy” rating in a report on Wednesday, December 18th. One analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Vericel presently has a consensus rating of “Moderate Buy” and a consensus target price of $63.14.

Vericel Trading Up 3.4 %

VCEL stock opened at $51.29 on Friday. Vericel has a twelve month low of $39.12 and a twelve month high of $63.00. The company has a market capitalization of $2.53 billion, a P/E ratio of 854.98 and a beta of 1.72. The firm has a 50 day simple moving average of $57.20 and a 200-day simple moving average of $51.83.

Insiders Place Their Bets

In other Vericel news, Director Robert L. Md Zerbe sold 2,500 shares of the stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $62.50, for a total value of $156,250.00. Following the transaction, the director now owns 26,595 shares of the company’s stock, valued at approximately $1,662,187.50. This represents a 8.59 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Jonathan Mark Hopper sold 10,000 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $58.72, for a total value of $587,200.00. Following the completion of the transaction, the insider now directly owns 58,371 shares in the company, valued at $3,427,545.12. The trade was a 14.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 20,100 shares of company stock valued at $1,206,072. 5.20% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Vericel

Large investors have recently modified their holdings of the business. Creative Planning bought a new position in shares of Vericel during the third quarter worth about $230,000. International Assets Investment Management LLC grew its holdings in shares of Vericel by 4,126.7% during the third quarter. International Assets Investment Management LLC now owns 634 shares of the biotechnology company’s stock worth $27,000 after buying an additional 619 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vericel by 22.2% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,773 shares of the biotechnology company’s stock worth $77,000 after buying an additional 322 shares in the last quarter. Conestoga Capital Advisors LLC grew its holdings in shares of Vericel by 1.7% during the third quarter. Conestoga Capital Advisors LLC now owns 2,075,730 shares of the biotechnology company’s stock worth $87,700,000 after buying an additional 34,360 shares in the last quarter. Finally, Farther Finance Advisors LLC grew its holdings in shares of Vericel by 48.1% during the third quarter. Farther Finance Advisors LLC now owns 1,247 shares of the biotechnology company’s stock worth $53,000 after buying an additional 405 shares in the last quarter.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.